my mhealth collaborates with AstraZeneca to improve asthma control

The partnership between my mhealth and AstraZeneca sees the integration of the Turbu+ Smarthaler device to improve medication adherence, asthma control and reduce asthma attacks.

Digital health tech pioneer, my mhealth announce their partnership with AstraZeneca integrating smarthaler technology into their respiratory digital therapeutics portfolio to support and improve outcomes for people with asthma.

All asthma patients are at risk of severe attacks, regardless of their disease severity. There are an estimated 176 million asthma attacks¹ globally per year, which are both physically and emotionally significant for many patients.

Despite asthma being a chronic, variable inflammatory disease, patients are either under-prescribed or under-use their anti-inflammatory "preventer" therapy and over-rely on their reliever medication, which can mask symptom worsening.

The device integration will help improve adherence and help patients take their medication correctly according to their my mhealth asthma action plan. Taking medication as prescribed can reduce the risk of an asthma attack and reduce inhaler wastage. Inhaler wastage and overuse of reliever metred dose inhalers contribute to greenhouse emissions and are a fundamental aspect of the NHS Net Zero initiative².

The integration of the Turbu+ device provides an upgrade to the current model available to patients using the Symbicort Turbuhaler on the my mhealth platform. The Turbu + is a sensor that sits on a Symbicort Turbuhaler inhaler and measures when patients have taken their medication. It measures the number of doses a patient uses and automatically synchronises this data to the app, helping patients and clinicians track medication adherence and ensuring the correct dose is received. Doses are recorded in the app medication diary automatically and a number of automated messages inform patients if they are taking it correctly. Clinical teams responsible for the patient can also view and track adherence using this functionality to help inform future prescribing decisions.

CEO and Founder of my mhealth, Dr Simon Bourne, commented:

"The Integration of Turbu+ into the myAsthma app has huge potential to improve patients symptoms and outcomes. The combination of our Asthma digital therapeutic with AstraZeneca Turbu+ device is just one of a series of programs with AstraZeneca to support patients with both Asthma and COPD in the UK."

If you're a pharma or life sciences business and want to know how my mhealth can help your business, you can find out more at www.mymhealth.com or by calling my mhealth on 0044 (0)1202 299 583

References

1. AstraZeneca (2019), New data show Symbicort reduces attacks in mild asthma when used as an anti-inflammatory reliever

2. Delivering a Net Zero National Health Service (2020)

Topics

asthma app pharma life sciences drug device combination AstraZeneca Turbu+

Further information

Email: info@mymhealth.com
Call: +44 (0)1202 299 583